M
Martha A. Sarpong
Researcher at GlaxoSmithKline
Publications - 15
Citations - 726
Martha A. Sarpong is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Transplantation & Cancer. The author has an hindex of 6, co-authored 15 publications receiving 674 citations.
Papers
More filters
Journal ArticleDOI
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Steven D. Knight,Nicholas D. Adams,Joelle Lorraine Burgess,Amita M. Chaudhari,Michael G. Darcy,Carla A. Donatelli,Juan I. Luengo,Ken A. Newlander,Cynthia A. Parrish,Lance Ridgers,Martha A. Sarpong,Schmidt Stanley J,Glenn S. Van Aller,Jeffrey D. Carson,Melody Diamond,Patricia A. Elkins,Christine M. Gardiner,Eric Garver,Seth A. Gilbert,Richard R. Gontarek,Jeffrey R. Jackson,Kevin L. Kershner,Lusong Luo,Kaushik Raha,Christian S. Sherk,Chiu-Mei Sung,David Sutton,Peter J. Tummino,Ronald Wegrzyn,Kurt R. Auger,Dashyant Dhanak +30 more
TL;DR: 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.
Patent
Quinoline derivatives as pi3 kinase inhibitors
Nicholas D. Adams,Joelle Lorraine Burgess,Darcy Michael Gerard,Carla A. Donatelli,Steven David Knight,Kenneth A. Newlander,Lance Ridgers,Martha A. Sarpong,Schmidt Stanley J +8 more
TL;DR: In this article, a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives was proposed, which is a method for treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
Journal ArticleDOI
Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase
Nicholas D. Adams,Jerry L. Adams,Joelle Lorraine Burgess,Amita M. Chaudhari,Robert A. Copeland,Carla A. Donatelli,David H. Drewry,Kelly E. Fisher,Toshihiro Hamajima,Mary Ann Hardwicke,William F. Huffman,Kristin K Koretke-Brown,Zhihong V Lai,Octerloney B. McDonald,Hiroko Nakamura,Ken A. Newlander,Catherine A. Oleykowski,Cynthia A. Parrish,Denis R. Patrick,Ramona Plant,Martha A. Sarpong,Kosuke Sasaki,Schmidt Stanley J,Domingos J. Silva,David Sutton,Jun Tang,Christine Thompson,Peter J. Tummino,Jamin C Wang,Hong Xiang,Jingsong Yang,Dashyant Dhanak +31 more
TL;DR: Key to the advancement of the series was the introduction of a 2-aryl group containing a basic amine onto the azaindole leading to significantly improved cellular activity leading to the identification of GSK1070916 (17k), a potent and selective ATP-competitive inhibitor of Aurora B and C.
Patent
Azaindole inhibitors of aurora kinases
Jerry L. Adams,Nicholas D. Adams,Jeffrey M. Axten,Amita M. Chaudhari,Dashyant Dhanak,Toshihiro Hamajima,Kenneth A. Newlander,Cynthia A. Parrish,Martha A. Sarpong,Silva Domingos J,Jun Tang +10 more
TL;DR: The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.
Patent
Quinoline derivatives as P13 kinase inhibitors
Nicholas D. Adams,Amita M. Chaudhari,Carla A. Donatelli,Steven D. Knight,Kenneth A. Newlander,Cynthia A. Parrish,Lance Ridgers,Martha A. Sarpong +7 more
TL;DR: In this article, a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives was proposed, which is a method for treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.